Zacks Bull and Bear of the Day Highlights: CEMIG, Health Management Associates, Jamba, Starbucks and Caribou Coffee
For Immediate Release
Chicago, IL – November 27, 2012 – Zacks Equity Research highlights CEMIG (CIG) as the Bull of the Day and Health Management Associates (HMA) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Jamba Inc. (JMBA), Starbucks Corporation (SBUX) and Caribou Coffee Company Inc. (CBOU).
Full analysis of all these stocks is available at http://at.zacks.com/?id=2678.
Here is a synopsis of all five stocks:
CEMIG's (CIG) 3Q12 results were impressive with its net income registering a 43% y/y increase and EPADR coming in at US$0.64. Net revenue grew 19% to US$2.4 billion on the back of a 1.7% increase in electricity sold to 17,715 GWh. We find the growth prospects for this Brazilian electricity utility bright.
Operating efficiencies, new projects and strategic acquisitions all bode well for the future. Moreover, with the growing electricity demand in Brazil as an important growth booster, the national agency predicts a consumption hike of about 4.5% in the 2011-2021 timeframe. The nation is growing faster with the government's increasing keenness to invest heavily in the electric industry.
The company is also doing every bit to increase its capacity in order to meet the escalating demand. Thus we upgrade our recommendation on the stock from Neutral to Outperform.
We downgrade our recommendation on Health Management Associates (HMA) to Underperform. Its third-quarter 2012 earnings per share of $0.18 missed the Zacks Consensus Estimate. We are wary about sustained volume pressure on the back of sluggish adjusted admissions.
The expected year-over-year decline in same hospital admissions implies declining volume trends for Health Management, and lackluster demand may worsen matters. Bad debt is another looming concern and may hurt earnings.
We refrain from suggesting the stock and are waiting to see if the company's business model and benefits from Obamacare can help Health Management to overcome the current headwinds and reimbursement uncertainties. We have a price target of $7.50, which is based on a P/E of approximately 9.3x our fiscal 2012 EPS estimate.
Latest Posts on the Zacks Analyst Blog:
Jamba Plans to Expand in California
Jamba Juice Company, a subsidiary of Jamba Inc. (JMBA), is planning a massive expansion in its home-court California, over the next six-to-seven years. The company’s growth plans include the launch of up to 120 stores in more than 100 business areas and 25 mall locations across Northern, Central and Southern California.
Jamba Juice currently operates more than 788 stores. The company plans to open the new stores through both new and existing franchises. It is also preparing for the launch of many company-owned stores.
The company’s founding state, California, remains an ideal location for development as it is one of the most populous and widespread state in the U.S. The promising restaurant industry in this state is a major driving force to the U.S. economy. In 2012, the total revenue from the restaurant sector in California is projected around $63.8 billion.
We believe that the development plan will further strengthen Jamba Juice’s position in its prime California market, going forward. However, the company will likely face stiff competition in that area from its peers like Starbucks Corporation (SBUX) and Caribou Coffee Company Inc. (CBOU).
Jamba has always remained focused on expansion and expects accelerated growth in both core existing markets as well as new geographic areas. For 2012, Jamba plans to open 40–50 new stores in the U.S. locations and 15 new stores internationally. In 2013, the company plans to further speed up its development process by opening 60 to 80 U.S. and international stores.
Jamba, currently carries a Zacks #3 Rank, which translates into a short-term ‘Hold’ rating. Our long-term recommendation for the stock remains Underperform.
Get the full analysis of all these stocks by going to http://at.zacks.com/?id=2649.
About the Bull and Bear of the Day
Every day, the analysts at Zacks Equity Research select two stocks that are likely to outperform (Bull) or underperform (Bear) the markets over the next 3-6 months.
About the Analyst Blog
Updated throughout every trading day, the Analyst Blog provides analysis from Zacks Equity Research about the latest news and events impacting stocks and the financial markets.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous analyst coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today by visiting http://at.zacks.com/?id=7158.
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment
Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=4582.
Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
Read the analyst report on CIG
Read the analyst report on HMA
Read the analyst report on JMBA
Read the analyst report on SBUX
Read the analyst report on CBOU
More From Zacks.com